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Abstract
Background/Aims
It is important to identify patients who are refractory to transarterial chemoembolization
(TACE), which is performed for the treatment of hepatocellular carcinoma (HCC). We inves-
tigated the predictors of poor treatment outcomes in patients with recurrent HCC treated
who were treated with TACE after curative resection.
Methods
428 patients with recurrent HCC after curative resection who were treated with TACE were
enrolled.
Results
The median age of the study population was 59.2 years. On multivariate analysis,�2 TACE
procedures within 6 months (hazard ratio [HR] = 1.898), and the des-gamma carboxypro-
thrombin level (HR = 1.000) independently predicted the progression to Barcelona Clinic
Liver Cancer (BCLC) stage C in patients with BCLC stage 0-B HCC (both P<0.05). In addi-
tion,�2 and�3 TACE procedures within 6 months independently predicted mortality in the
entire study population (HR = 1.863 and 1.620, respectively). The probability of progression
to BCLC stage C in patients with BCLC stage 0-B HCC and the mortality rate in the entire
study population were significantly higher in patients treated with�2 TACE within 6 months
than in those who underwent fewer procedures (P = 0.002 and P<0.001, respectively).
Conclusions
More than 2 TACE procedures within 6 months might be associated with the refractoriness
to TACE in patients with recurrent HCC after curative resection.
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Introduction
Hepatocellular carcinoma (HCC) is ranked as the 5th most common cancer worldwide, and
the 3rd leading cause of death [1, 2]. Although ultrasound-based surveillance for HCC is appli-
cable in clinical practice, HCC is still diagnosed in the late stage in a significant proportion of
patients, for which only palliative treatments such as transarterial chemoembolization
(TACE), targeted systemic or hepatic arterial infusion chemotherapies are available. However,
if HCC is detected in the early stage, several treatment options such as liver transplantation,
surgical resection, or ablative therapy can be attempted with a curative intents [3].
Hepatic resection has been considered the mainstay of curative treatment for HCC, and
offers a significantly better survival [4–6]. However, due to the high risk of recurrence despite
curative resection, the long-term outcomes of patients with HCC who underwent resection
remain unsatisfactory [7]. In contrast to the ultrasound-based surveillance of patients without
HCC, the intensive follow-up strategy with dynamic imaging modalities, such as computed
tomography (CT) or magnetic resonance imaging (MRI) after HCC resection has increased
the possibility of detecting HCC recurrence at the early stage. However, re-resection is not
always feasible because of technical difficulties such as postoperative adhesion, insufficient
remnant liver volume, or patient refusal [8]. Thus, TACE has been frequently performed to
control recurrent HCC after resection, if there is no evidence of extra-hepatic metastasis or
vessel invasion [9–11].
On the basis of the reported survival benefit of TACE, TACE has been widely used for
patients with Barcelona Clinic Liver Cancer (BCLC) intermediate stage HCC [10, 12, 13].
However, recent studies have shown that repeated TACE sessions within a short period due to
incomplete response or appearance of new lesions can cause stage progression or the deterio-
ration of liver function even for intermediate-stage HCC [14].
When only targeted systemic therapy for patients with stage-migrated HCC or conservative
managements for those with deteriorated liver function are available, poor survival is expected [3,
15]. However, molecular target or immunotherapeutic agents can be considered, when the poor
outcomes are expected after repeated TACEs in patients with multiple tumors, major vessel inva-
sion, hypovascularity, or borderline liver function. Thus, it might be important to identify patients
at high-risk for TACE refractoriness and set up the optimal timing to switch treatment modality,
because early detection of TACE refractoriness would enable early amendments in the treatment
strategy and better survival outcomes [14]. Indeed, several studies have shown that the early
switch from TACE to sorafenib significantly prolonged overall survival when compared with
adherence to repeated TACEs among patients with TACE refractoriness [15].
Although TACE has been frequently performed in patients with recurrent HCC after cura-
tive resection and the concept of TACE refractoriness has been previously demonstrated, it is
not known whether the term “TACE refractoriness” is applicable in patients with recurrent
HCC after curative resection. Thus, we aimed to identify the predictors of stage progression
and mortality during repeated TACE sessions, and to define TACE refractoriness in patients
with recurrent HCC after curative resection.
Materials and methods
Patients
Through a retrospective review of the prospectively registered data bank of Yonsei Liver Cen-
ter, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, eligible patients
with recurrent HCC after curative resection between 2006 and 2015 were considered for inclu-
sion in this study. The exclusion criteria were as follows: 1) anti-cancer treatments other than
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TACE; 2) combined use of other anti-cancer treatments and TACE; 3) serious medical comor-
bidity; 4) BCLC stage D; 5) extrahepatic metastasis; and 6) insufficient clinical information
(Fig 1). All relevant data are available with Supporting Information files (S1 Dataset).
The study protocol was in accordance with the ethics guidelines of the 1975 Declaration of
Helsinki and the study procedure was approved by the institutional review board of Severance
Hospital. The need for written informed consent was waived because of the retrospective
nature of the study.
Diagnosis and staging of HCC
According to the guidelines proposed by the Korea Liver Cancer Study group [16], HCC is diag-
nosed if patient has 1 or more risk factors (chronic viral hepatitis or cirrhosis) and any 1 of the fol-
lowing: 1) serum alpha-fetoprotein (AFP) level>400 ng/mL and at least 1 positive finding for
typical HCC on dynamic CT, MRI, or hepatic angiography; 2) serum AFP<400 ng/mL and at
least 2 positive findings for typical HCC on those imaging studies. A positive finding for typical
HCC on dynamic CT or MRI was defined as increased arterial enhancement followed by decreased
enhancement compared with the liver (washout) in the portal or equilibrium phase [16–18].
TACE procedure
TACE was performed through selective infusion of a mixture of iodized oil contrast medium
(Lipiodol; Guerbet, Aulnay-sous-Bois, France) and doxorubicin (Adriamycin; Ildong Pharma-
ceutical, Seoul, Korea) followed by embolization of feeding arteries using gelatin sponge parti-
cles (Cutanplast; Mascia Brunelli S.p.A., Milan, Italy). Embolization was performed until stasis
was achieved in the second- or third- order branches of the right or left hepatic arteries [19].
TACE was repeated on an “on-demand” basis at 6- to 8-week intervals when a residual viable
tumor or new intrahepatic lesions was detected in the liver on a follow-up assessment, in the
absence of extrahepatic metastases, major portal vein invasion, or deterioration in clinical sta-
tus or laboratory values [20].
Fig 1. Flowchart of the study population. A total of 770 patients with hepatocellular carcinoma (HCC) underwent curative resection between 2006 and 2015 in our
training cohort. After the application of exclusion criteria, the training cohort consisted of 428 patients who underwent transarterial chemoembolization because of
recurrent HCC after curative resection.
https://doi.org/10.1371/journal.pone.0214613.g001
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Assessment of treatment responses
HCC staging and response evaluation at the time of recurrence or after TACE was done by
radiologists who were aware of treatment history of TACEs. Treatment responses were
assessed 4 weeks after the initial TACE by using a modified Response Evaluation Criteria in
Solid Tumors (RECIST) guideline [3, 19, 21]. The modified RECIST guideline defines viable
tumors according to uptake of contrast material in the arterial phase of dynamic CT or MRI;
tumors retaining iodized oil and necrotic lesions without intratumoral arterial enhancement
were considered necrotized tumor foci.
Statistical analysis
The baseline characteristics of the patients are expressed as median (interquartile range, or n
(%), as appropriate. Independent t-test (or Mann-Whitney test) and chi-square test (or Fisher’s
exact test) were used to compare the characteristics between the subgroups with early (� 2
years) and late (> 2 years) recurrence of HCC after curative resection [22]. Univariate and
multivariate Cox regression hazard models were used to produce crude and adjusted hazard
ratios (HRs) and their 95% confidence intervals (95% CIs) for potential risk factors. Variables
with a P value of<0.05 in univariate analyses were included in the multivariate models. A P
value of<0.05 was considered statistically significant. The cumulative stage-progression free-
survival and overall survival rates were estimated using the Kaplan-Meier method, and median
survival times and their 95% CIs are reported. The log-rank test was used to assess and com-
pare the survival differences between the groups. All statistical analyses were performed using
SPSS 23.0 for Windows (IBM Corp., Armonk, NY, USA).
Results
Patient characteristics
A total of 770 patients with recurrent HCC after curative resection between January 2006 and
December 2015 were considered eligible. Of them, 511 patients treated with TACE as the first-
line anti-cancer treatment were selected. After excluding 83 patients according to our exclu-
sion criteria, 428 patients were finally selected for the statistical analysis (Fig 1).
The baseline characteristics of 428 patients are summarized in Table 1. The median age of
the study population was 59.2 (interquartile range [IQR], 52.2–66.6) years and male patients
predominated (n = 362, 84.6%). Most patients had preserved liver function (Child-Pugh class
A, n = 419, 97.9%), and the main etiology was hepatitis B virus infection (n = 348, 81.3%). The
median AFP and des-gamma carboxyprothrombin (DCP) was 7.6 ng/mL and 31 mAU/mL,
respectively. Around half of the study population had multiple tumors (n = 198, 46.3%), and
portal vein invasion was identified in 26 (6.1%) patients. BCLC stage 0, A, B, and C HCC was
observed in 109 (25.5%), 137 (32.0%), 68 (15.9%), and 114 (26.6%) patients, respectively. Mul-
tiple tumors and portal vein invasion were observed in 70 (16.4%), and 26 (6.1%) patients, and
the median maximal tumor size was 3.5 (IQR, 2.5–5.2) cm at the time of resection. The median
duration from resection to the first TACE was 17.9 (IQR 7.2–37.1) months.
Comparison between patients treated with TACE according to time of
HCC recurrence
When our study population was divided into 2 groups with early (� 2 years, n = 255, 59.6%)
and late (> 2 years, n = 173, 40.4%) recurrence [22], patients with early recurrence were signif-
icantly younger (median 57.8 vs. 62.0 years) and had a significantly higher incidence of diabe-
tes (23.1% vs. 14.5%), a higher DCP level (median 33 vs. 27 mAU/mL), a higher incidence of
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multiple tumors (56.1% vs. 31.8%), a lower incidence of BCLC stage 0-A HCC (49.0% vs.
69.9%), and a higher maximal tumor size at the time of recurrence than those with late recur-
rence (all P<0.05) (Table 2).
Progression to BCLC stage C during repetitive TACEs
A total of 314 patients had BCLC stage 0-B HCC at the time of recurrence (109 with BCLC
stage 0, 137 with BCLC stage A, and 68 with BCLC stage B). Among patients with BCLC stage
0 at the time of recurrence, 38 (32.5%) experienced progression to BCLC stage C after a
median follow-up of 17.5 (IQR 8.0–51.7) months. In addition, 47 (40.2%) patients with BCLC
stage A and 32 (27.3%) patients with BCLC stage B at the time of recurrence progressed to
BCLC stage C after a median follow-up of 19.0 (IQR 7.5–39.2) and 18.0 (IQR 12.1–40.4)
months, respectively (Fig 2).
Table 1. Baseline characteristics of the study population at the time of 1st TACE due to recurrent HCC after cura-
tive resection (n = 428).
Variables Values
Demographic variables
Age, years 59.2 (52.2–66.6)
Male gender 362 (84.6)
Diabetes mellitus 84 (19.6)
Ultrasonographic cirrhosis 178 (41.6)
Histological cirrhosis 263 (61.4)
Child-Pugh class, A/B 419 (97.9)/ 9 (2.1)
Etiology
HBV/ HCV/ alcohol/ others 348 (81.3)/ 36 (8.4) / 13 (3.0) / 31 (7.2)
Laboratory variables
Alanine aminotransferase, IU/L 26 (18–37)
Serum albumin, g/dL 4.0 (3.7–4.3)
Total bilirubin, mg/dL 0.8 (0.6–1.0)
Prothrombin time, INR 1.01 (0.97–1.06)
Platelet count, x103/mm3 127 (96–165)
Alpha-fetoprotein, ng/mL 7.6 (3.0–74.5)
Des-gamma carboxyprothrombin, mAU/mL 31 (20–69)
Tumor variables
Multiple tumors 198 (46.3)
Maximal tumor size, cm 1.6 (1.2–2.2)
Infiltrative pattern 8 (1.9)
Portal vein invasion 26 (6.1)
BCLC stage
0/ A/ B/ C 109 (25.5) / 137 (32.0) / 68 (15.9) / 114 (26.6)
Tumor variables at the time of resection
Multiple tumors 70 (16.4)
Maximal tumor size, cm 3.5 (2.5–5.2)
Portal vein invasion 32 (7.5)
Time from resection to the 1st TACE, months 17.8 (7.2–37.1)
Variables are expressed as n (%) or median (interquartile range).
TACE, transarterial chemoembolization; HCC, hepatocellular carcinoma; HBV, Hepatitis B virus; HCV, hepatitis C
virus; INR, international normalized ratio; BCLC, Barcelona clinic liver cancer.
https://doi.org/10.1371/journal.pone.0214613.t001
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Predictors of progression to BCLC stage C (BCLC stage 0-B only)
On univariate analysis, DCP level, and�2 TACEs within 6 months were significantly associ-
ated with progression to BCLC stage C in patients with BCLC stage 0-B only (all P<0.05)
(Table 3). On multivariate analyses, DCP level and�2 TACEs within 6 months were indepen-
dently associated with a higher risk of progression to BCLC stage C (HR = 1.000, 95% CI
1.000–1.001, P<0.001; HR = 1.898, 95% CI 1.265–2.846, P = 0.002, respectively) (Table 3).
More than 2 TACEs within 6 months showed a borderline statistical significance in the sub-
group with early recurrence (� 2 years, n = 176, 56.1%) (P = 0.053), whereas it was not signifi-
cant in the subgroup with late recurrence (>2 years, n = 138, 43.9%) (P>0.05) (Table 4).
Predictors of mortality
In the entire cohort, on univariate analyses, lower serum albumin level, higher prothrombin
time, AFP level>100 ng/mL, multiple tumors, and�2 or�3 TACEs within 6 months were
significantly associated with a higher risk of mortality (all P<0.05) (Table 5). On multivariate
analysis using�2 TACEs,�2 TACEs within 6 months independently predicted a higher risk
Table 2. Comparison between patients treated with TACE due to early (� 2 years) and late (> 2 years) recurrence after curative resection.
Variables Patients with early recurrence Patients with late recurrence P value
(n = 255, 59.6%) (n = 173, 40.4%)
Demographic variables
Age, years 57.8 (50.9–65.5) 62.0 (54.4–68.0) <0.001
Male gender 212 (83.1) 150 (86.7) 0.316
Diabetes mellitus 59 (23.1) 25 (14.5) 0.026
Ultrasonographic cirrhosis 94 (36.9) 84 (48.6) 0.273
Histological cirrhosis 158 (62.0) 105 (60.7) 0.792
Child-Pugh class, A/B 249 (97.7)/ 6 (2.4) 170 (98.3)/ 3 (1.7) 0.745
Viral etiology 226 (88.7) / 29 (11.3) 158 (91.3) / 15 (8.7) 0.366
Laboratory variables
Alanine aminotransferase, IU/L 26 (20–38) 23 (17–33) 0.199
Serum albumin, g/dL 3.9 (3.6–4.2) 4.1 (3.7–4.3) 0.059
Total bilirubin, mg/dL 0.7 (0.6–1.0) 0.8 (0.6–1.1) 0.074
Prothrombin time, INR 1.02 (0.97–1.07) 1.00 (0.96–1.06) 0.122
Platelet count, x103/mm3 127 (96–163) 128 (96–166) 0.601
Alpha-fetoprotein, ng/mL 10.9 (3.6–104.4) 5.0 (2.7–27.6) 0.166
Des-gamma carboxyprothrombin, mAU/mL 33 (21–78) 27 (18–57) 0.043
Tumor variables
Multiple tumors 143 (56.1) 55 (31.8) <0.001
Maximal tumor size, cm 1.5 (1.1–2.1) 1.6 (1.3–2.3) 0.205
Infiltrative pattern 5 (2.0) 3 (1.7) 0.846
Portal vein invasion 13 (5.1) 13 (7.5) 0.304
BCLC stage, 0-A/ B-C 125 (49.0) / 130 (51.0) 121 (69.9) / 52 (30.1) <0.001
Tumor variables at the time of resection
Multiple tumors 47 (18.4) 23 (13.3) 0.160
Maximal tumor size, cm 4.0 (2.7–5.8) 3.1 (2.2–4.5) 0.001
Portal vein invasion 21 (8.2) 11 (6.4) 0.471
Variables are expressed as n (%) or median (interquartile range).
TACE, transarterial chemoembolization; INR, international normalized ratio; BCLC, Barcelona clinic liver cancer.
https://doi.org/10.1371/journal.pone.0214613.t002
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of mortality (HR = 1.863, 95% CI 1.372–2.530, P<0.001), together with lower serum albumin
level, AFP level>100 ng/mL, and multiple tumors (all P<0.05) (Table 5). In addition, on mul-
tivariate analysis of�3 TACEs,�3 TACEs within 6 months independently predicted a higher
risk of mortality (HR = 1.620, 95% CI 1.029–2.551, P = 0.037), together with lower serum albu-
min level, AFP level >100 ng/mL, and multiple tumors (all P<0.05) (Table 5).
In the subgroup with early recurrence (� 2 years),�2 TACEs within 6 months indepen-
dently predicted a higher risk of mortality (HR = 1.629, 95% CI 1.134–2.340, P = 0.008),
together with lower serum albumin level and multiple tumors (all P<0.05), whereas�3
TACEs within 6 months was not significant in univariate analysis (P = 0.075) (S1 Table). In
the subgroup with late recurrence (>2 years),�2 and�3 TACEs within 6 months were inde-
pendently associated with increased risk of mortality (HR = 2.386, 95% CI 1.268–4.488,
P = 0.007 and HR = 9.297, 95% CI 2.087–41.405, P = 0.003, respectively), together with lower
serum albumin level, higher prothrombin time, and higher DCP level (all P<0.05) (S1 Table).
Progression-free survival rate to BCLC stage C (BCLC 0-B only) and
overall survival rate
The progression-free survival to BCLC stage C were significantly associated with between <2
and�2 TACEs within 6 months in patients with only BCLC stage 0-B (P = 0.003, log-rank
test), and the overall survival rates were significantly associated with between<2 and�2
TACEs within 6 months in the entire cohort (P<0.001, log-rank test) (Fig 3). The progres-
sion-free survival rates at 5-years were 65.6% for<2 TACEs and 49.7% for�2 TACEs within 6
Fig 2. Distribution of progression among patients with Barcelona Clinic Liver Cancer (BCLC) stage C among patients with BCLC stage 0-B.
Among patients with BCLC stage 0 at the time of recurrence, 38 patients with BCLC stage 0, 47 patients with BCLC stage A, and 32 patients with
BCLC stage B experienced progression to BCLC stage C.
https://doi.org/10.1371/journal.pone.0214613.g002
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months in patients with only BCLC stage 0-B, and the overall survival rates at 5-years, were
55.8% for<2 TACEs and 26.0% for�2 TACEs within 6 months in the entire cohort (Fig 3).
Discussion
In this study, we found that�2 TACEs within 6 months because of recurrent HCC after cura-
tive resection independently predicted progression to BCLC stage C in the subgroup of
patients with BCLC stage A or B at the time of recurrence (HR = 1.898). In addition,�2 and
�3 TACEs within 6 months were independently associated with increased risk of mortality
(HR = 1.863 and 1.620, respectively), and�2 TACEs independently predicted mortality
regardless of the recurrence time point (HR = 1.629 in the subgroup with early recurrence and
HR = 2.386 in the subgroup with late recurrence). The presence of�3 TACEs was also inde-
pendently predictive of mortality in the subgroup with late recurrence (HR = 9.297).
It is well known that TACE provides survival benefit for patients with intermediate-stage
HCC, defined as large, unresectable or multinodular HCC [10, 23]. However, because the pri-
mary aim of TACE is palliative management, it should be carefully performed to prolong sur-
vival in the presence of TACE-associated morbidity and mortality. Indeed, TACE may worsen
the underlying liver dysfunction, especially when repeated TACEs are required. Moreover
TACE has an up to 10% risk rate of potential procedure-related mortality [14]. Before the era
of molecular targeted treatments, TACE has been frequently repeatedly performed due to the
absence of alternative treatment modalities, even when poor patient response was anticipated
[14]. However, because several molecular targeted agents, including sorafenib, are now avail-
able based on their proven treatment efficacy from several randomized trials [24], the concept
Table 3. Independent predictors of stage progression to BCLC stage C among patients with recurrent HCC after curative resection (BCLC 0-B only).
Variables Univariate Multivariate analysis
P value HR 95% CI P value
At the time of recurrence
Age 0.073
Male gender 0.532
Diabetes mellitus 0.677
Alanine aminotransferase, IU/mL 0.063
Serum albumin, g/dL 0.059
Total bilirubin, mg/dL 0.996
Prothrombin time, INR 0.875
Platelet count, x103/mm3 0.765
Alpha-fetoprotein > 100, ng/mL 0.376
Des-gamma carboxyprothrombin, mAU/mL <0.001 1.000 1.000–1.001 <0.001
Multiple tumors 0.170
Maximal tumor size >5cm 0.745
More than 2 TACEs within 6 months 0.003 1.898 1.265–2.846 0.002
More than 3 TACEs within 6 months 0.051
At the time of resection
Multiple tumors 0.407
Maximal tumor size >5cm 0.177
BCLC, Barcelona clinic liver cancer; HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; INR, international normalized ratio; TACE, trans-
arterial chemoembolization.
https://doi.org/10.1371/journal.pone.0214613.t003
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of TACE refractoriness was proposed to prevent the deterioration of liver function or stage
progression during repeated TACE sessions [15, 24–26].
The Japan Society of Hepatology (JSH) and the Liver Cancer Study Group of Japan in 2010
introduced the concept of TACE refractoriness (� 2 ineffective responses of the treated tumor
[viable lesions >50%] or� 2 progressive increases in total tumor counts, continuous elevation
of the levels of tumor markers, or appearance of vascular invasion extrahepatic spread) [27,
28]. Because the change in arterial enhancement of HCC should be repeatedly assessed after
each TACE session to define TACE refractoriness [29], the JSH criteria for TACE refractori-
ness might be inconvenient for hepatologists or oncologists. In contrast, Kim et al. [14] defined
TACE refractoriness according to the number of TACE sessions within a limited period (� 3
TACEs within 6 months), which was significantly associated with an increased risk of stage
progression and accordingly was incorporated into the Korean Association for the Study of
the Liver guideline [16]. This criterion for TACE refractoriness based on the number of TACE
sessions with in a restricted period might be easy to use in clinical practice.
Although several factors were significantly different between patients with early recurrence
and those with late recurrence in our study,� 2 TACE within 6 months for recurrent HCC
after curative resection independently predicted progression to BCLC stage C among patients
with BCLC stager 0-B at the time of the first TACE. In addition, the progression free survival
to BCLC stage C was significantly different between the subgroups with<2 TACEs and�2
TACEs within 6 months. However, probably due to the relatively small sample size of the sub-
groups with early and late recurrence, the independent influence of� 2 TACEs within 6
months was not reproduced in the subgroup analysis. In contrast to our study, Kim et al.
reported� 3 TACEs within 6 months as an independent predictor of stage progression [14].
Table 4. Independent predictors of stage-progression in patients with early and late HCC recurrence after curative resection (BCLC 0-B only).
Variables � 2-years (n = 176, 56.1%) > 2-years (n = 138, 43.9%)
Univariate Multivariate analysis Univariate Multivariate analysis
P value HR 95% CI P value P value HR 95% CI P value
At the time of recurrence
Age 0.991 0.409
Male gender 0.609 0.388
Diabetes mellitus 0.995 0.790
Alanine aminotransferase, IU/mL 0.274 0.390
Serum albumin, g/dL 0.115 0.764
Total bilirubin, mg/dL 0.752 0.350
Prothrombin time, INR 0.257 0.441
Platelet count, x103/mm3 0.807 0.920
Alpha-fetoprotein > 100, ng/mL 0.578 0.134
Des-gamma carboxyprothrombin, mAU/mL 0.001 1.000 1.000–1.001 0.001 0.049 1.002 1.000–1.005 0.089
Multiple tumors 0.369 0.986
Maximal tumor size >5cm 0.586 0.019 7.748 0.950–63.201 0.056
More than 2 TACEs within 6 months 0.053 0.317
More than 3 TACEs within 6 months 0.369 0.751
At the time of resection
Multiple tumors 0.485 0.847
Maximal tumor size >5cm 0.233 0.961
HCC, hepatocellular carcinoma; BCLC, Barcelona clinic liver cancer; HR, hazard ratio; CI, confidence interval; INR, international normalized ratio; TACE, transarterial
chemoembolization.
https://doi.org/10.1371/journal.pone.0214613.t004
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Table 5. Independent predictors of mortality among patients with recurrent HCC after curative resection.
Variables Univariate Multivariate analysis� Multivariate analysis��
P value HR 95% CI P value HR 95% CI P value
At the time of recurrence
Age 0.247
Male gender 0.961
Diabetes mellitus 0.545
Alanine aminotransferase, IU/mL 0.446
Serum albumin, g/dL <0.001 0.547 0.391–0.767 <0.001 0.538 0.384–0.755 <0.001
Total bilirubin, mg/dL 0.900
Prothrombin time, INR <0.001 3.713 0.916–15.054 0.066 3.700 0.906–15.108 0.068
Platelet count, x103/mm3 0.205
Alpha-fetoprotein > 100, ng/mL 0.015 1.495 1.071–2.087 0.018 1.527 1.092–2.136 0.013
Des-gamma carboxyprothrombin, mAU/mL 0.287
Multiple tumors <0.001 1.569 1.174–2.097 0.002 1.597 1.189–2.145 0.002
Maximal tumor size >5cm 0.104
More than 2 TACEs within 6 months <0.001 1.863 1.372–2.530 <0.001
More than 3 TACEs within 6 months 0.001 1.620 1.029–2.551 0.037
At the time of resection
Multiple tumors 0.448
Maximal tumor size >5cm 0.644
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; INR, international normalized ratio; TACE, transarterial chemoembolization.
Multivariate analysis� and �� includes�2 and�3 TACEs within 6 months as a variable for multivariate analysis, respectively.
https://doi.org/10.1371/journal.pone.0214613.t005
Fig 3. Cumulative incidence rates of progression to Barcelona Clinic Liver Cancer (BCLC) stage C among patients with BCLC stage 0-B (A) and mortality in the
entire population (B) with�2 and<2 TACEs within 6 months (all P<0.05, log-rank test).
https://doi.org/10.1371/journal.pone.0214613.g003
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Although the reason for this discrepancy is not clear, it can be explained in part by the different
characteristics between treatment-naïve patients who started anti-cancer treatment with
TACE and those treated with TACE due to recurrent HCC after curative resection.
In patients who underwent curative resection, HCC recurrence might be detected in the
early stage probably because of the intensive surveillance involving frequent dynamic imaging
studies. Indeed, in our study population, the median maximal tumor size was less than 2cm
and around three-fourths of the patients had BCLC stage 0-B HCC at the time of recurrence.
In addition, patients who underwent surgical resection might have well-preserved liver func-
tion preoperatively. However, a pre-existing history of HCC treatment itself (resection) and
the potential vulnerability to liver deterioration due to repeated TACEs, because of reduced
liver volume after resection might be associated with the fewer requited TACE sessions to
define TACE refractoriness in patients with recurrent HCC after resection. Similarly, the asso-
ciation between� 2 TACEs within 6 months and the increased risk of mortality can be
explained.
Our study has several strengths. First, this study has a relatively large sample size, with a
long-term follow-up period (median 32.1 months, up to 59.3 months). These factors might
have increased the statistical power of our study and enabled us to identify poor prognostic
factors for long-term prognosis in our cohort. Second, to the best of our knowledge, this study
is the first to identify the prognostic factors of stage progression and mortality and to establish
“TACE refractoriness” optimized for patients who underwent TACE because of recurrent
HCC after resection. Third, although discrepant characteristics or pathophysiologies might
exist, we also confirmed that the term “TACE refractoriness” might be adaptable, regardless of
the time point of HCC recurrence.
Several issues remain unresolved in our study. First, our study was a single center, retro-
spective study. Although our study has a large sample size and long-term follow-up period,
with strong statistical power, our results need to be further validated in a large-scale prospec-
tive study. Second, in case of TACE refractoriness, the proportion of patients who received sor-
afenib was extremely low; thus, further prospective, randomized control studies investigating
whether switching to sorafenib, based on the concept of TACE refractoriness proposed in our
study, can provide a survival benefit are strongly required. Third, our study mainly focused on
the number of TACE sessions without considering the reasons why repeated TACEs were
required, such as incomplete previous TACE or the development of new lesions. As the pres-
ence of� 2 ineffective responses seen in > 50% according to the modified RECIST criteria is
defined as TACE refractoriness in the JSH guideline [28], further studies are needed to validate
whether the prognostic value of our simple definition of TACE refractoriness would be com-
parable to that of the JSH.
In conclusion, the progression-free survival rates and overall survival rates in patients
treated with repeated TACEs due to recurrent HCC after resection were poor in patients who
underwent� 2 TACEs. Thus,� 2 TACEs within 6 months could also be defined as TACE
refractoriness in our cohort of patients with recurrent HCC after curative resection who were
treated with TACE. However, whether maintaining repeated TACEs or switching to the next-
step treatment, such as molecular targeted agents, would provide a better survival benefit
should further be investigated.
Supporting information
S1 Dataset. Spreadsheet with the minimal data set underlying the results.
(XLSX)
Refractoriness to TACE after resection
PLOS ONE | https://doi.org/10.1371/journal.pone.0214613 April 4, 2019 11 / 14
S1 Table. Independent predictors of mortality among patients with early and late HCC
recurrence after curative resection.
(DOCX)
Author Contributions
Conceptualization: Seung Up Kim.
Data curation: Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong
Park, Do Young Kim, Gi Hong Choi, Jin Sub Choi.
Formal analysis: Mi Young Jeon, Hye Soo Kim.
Investigation: Gi Hong Choi.
Methodology: Sang Hoon Ahn.
Resources: Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim.
Supervision: Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jin Sub Choi, Kwang-Hyub
Han.
Writing – original draft: Mi Young Jeon, Hye Soo Kim.
Writing – review & editing: Mi Young Jeon, Seung Up Kim.
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a
cancer journal for clinicians. 2015; 65(2):87–108. Epub 2015/02/06. https://doi.org/10.3322/caac.21262
PMID: 25651787.
2. Xu X, Mack C, Cleland ZJ, Vallabh CKP, Dave VS, Cetinkaya C. Correlation of solid dosage porosity
and tensile strength with acoustically extracted mechanical properties. International journal of pharma-
ceutics. 2018; 542(1–2):153–63. Epub 2018/03/15. https://doi.org/10.1016/j.ijpharm.2018.03.018
PMID: 29535040.
3. Kim BK, Kim SU, Kim KA, Chung YE, Kim MJ, Park MS, et al. Complete response at first chemoemboli-
zation is still the most robust predictor for favorable outcome in hepatocellular carcinoma. Journal of
hepatology. 2015; 62(6):1304–10. Epub 2015/02/01. https://doi.org/10.1016/j.jhep.2015.01.022 PMID:
25637785.
4. Kim JY, Sinn DH, Gwak GY, Choi GS, Saleh AM, Joh JW, et al. Transarterial chemoembolization ver-
sus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clinical and molecular hepa-
tology. 2016; 22(2):250–8. Epub 2016/07/06. https://doi.org/10.3350/cmh.2016.0015 PMID: 27377909;
PubMed Central PMCID: PMCPMC4946408.
5. Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, et al. Applicability of BCLC stage for prognostic
stratification in comparison with other staging systems: single centre experience from long-term clinical
outcomes of 1717 treatment-naive patients with hepatocellular carcinoma. Liver international: official
journal of the International Association for the Study of the Liver. 2012; 32(7):1120–7. Epub 2012/04/25.
https://doi.org/10.1111/j.1478-3231.2012.02811.x PMID: 22524688.
6. Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, et al. Survival outcomes of hepatic resection
compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal
vein tumor thrombosis. Clinical and molecular hepatology. 2016; 22(1):160–7. Epub 2016/04/06.
https://doi.org/10.3350/cmh.2016.22.1.160 PMID: 27044767; PubMed Central PMCID:
PMCPMC4825165.
7. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recur-
rence after resection of hepatocellular carcinoma. Annals of surgery. 2000; 232(1):10–24. Epub 2000/
06/22. PMID: 10862190; PubMed Central PMCID: PMCPMC1421103.
8. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma
increases the chance of treatment: Hong Kong experience. Hepatology (Baltimore, Md). 2000; 31
(2):330–5. Epub 2000/02/03. https://doi.org/10.1002/hep.510310211 PMID: 10655254.
9. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoemboli-
sation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a
Refractoriness to TACE after resection
PLOS ONE | https://doi.org/10.1371/journal.pone.0214613 April 4, 2019 12 / 14
randomised controlled trial. Lancet (London, England). 2002; 359(9319):1734–9. Epub 2002/06/07.
https://doi.org/10.1016/S0140-6736(02)08649-X PMID: 12049862.
10. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial
lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (Baltimore, Md).
2002; 35(5):1164–71. Epub 2002/05/01. https://doi.org/10.1053/jhep.2002.33156 PMID: 11981766.
11. Rosen HR, Ghany MG, Chung RT, Lok ASF. NAM 2017 report: A national plan to eliminate hepatitis B
and C in the United States by 2030 and the AASLD’s response. Hepatology (Baltimore, Md). 2017; 66
(4):1020–2. Epub 2017/07/18. https://doi.org/10.1002/hep.29361 PMID: 28714210.
12. Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma
around the world: 2010–2016. Clinical and molecular hepatology. 2016; 22(1):7–17. Epub 2016/04/06.
https://doi.org/10.3350/cmh.2016.22.1.7 PMID: 27044761; PubMed Central PMCID:
PMCPMC4825164.
13. Kim JH, Sinn DH, Shin SW, Cho SK, Kang W, Gwak GY, et al. The role of scheduled second TACE in
early-stage hepatocellular carcinoma with complete response to initial TACE. Clinical and molecular
hepatology. 2017; 23(1):42–50. Epub 2017/03/07. https://doi.org/10.3350/cmh.2016.0058 PMID:
28263954; PubMed Central PMCID: PMCPMC5381828.
14. Kim HY, Park JW, Joo J, Jung SJ, An S, Woo SM, et al. Severity and timing of progression predict
refractoriness to transarterial chemoembolization in hepatocellular carcinoma. J Gastroenterol Hepatol.
2012; 27(6):1051–6. https://doi.org/10.1111/j.1440-1746.2011.06963.x PMID: 22098152.
15. Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion
chemotherapy and molecular targeted therapy. Liver cancer. 2012; 1(2):62–70. Epub 2013/10/26.
https://doi.org/10.1159/000342402 PMID: 24159574; PubMed Central PMCID: PMCPMC3747546.
16. Korean Liver Cancer Study G, National Cancer Center K. [Practice guidelines for management of hepa-
tocellular carcinoma 2009]. The Korean journal of hepatology. 2009; 15(3):391–423. Epub 2009/09/29.
https://doi.org/10.3350/kjhep.2009.15.3.391 PMID: 19783891.
17. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-
EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology.
2012; 56(4):908–43. Epub 2012/03/20. https://doi.org/10.1016/j.jhep.2011.12.001 PMID: 22424438.
18. Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): sum-
mary, discussion, and consensus of the LI-RADS Management Working Group and future directions.
Hepatology (Baltimore, Md). 2015; 61(3):1056–65. Epub 2014/07/22. https://doi.org/10.1002/hep.
27304 PMID: 25041904.
19. Park Y, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Addition of tumor multiplicity improves the
prognostic performance of the hepatoma arterial-embolization prognostic score. Liver international: offi-
cial journal of the International Association for the Study of the Liver. 2016; 36(1):100–7. Epub 2015/05/
28. https://doi.org/10.1111/liv.12878 PMID: 26013186.
20. Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, et al. Prospective comparison of prognostic val-
ues of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study
of the Liver criteria in hepatocellular carcinoma following chemoembolisation. European journal of can-
cer (Oxford, England: 1990). 2013; 49(4):826–34. Epub 2012/09/22. https://doi.org/10.1016/j.ejca.
2012.08.022 PMID: 22995582.
21. Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, et al. Reproducibility of European Association
for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients
treated with sorafenib. Liver international: official journal of the International Association for the Study of
the Liver. 2018. Epub 2018/03/02. https://doi.org/10.1111/liv.13731 PMID: 29495116.
22. Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S, et al. Optimal duration of the
early and late recurrence of hepatocellular carcinoma after hepatectomy. World journal of gastroenterol-
ogy. 2015; 21(4):1207–15. Epub 2015/01/30. https://doi.org/10.3748/wjg.v21.i4.1207 PMID: 25632194;
PubMed Central PMCID: PMCPMC4306165.
23. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial
chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology.
2006; 131(2):461–9. Epub 2006/08/08. https://doi.org/10.1053/j.gastro.2006.05.021 PMID: 16890600.
24. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocel-
lular carcinoma. The New England journal of medicine. 2008; 359(4):378–90. Epub 2008/07/25. https://
doi.org/10.1056/NEJMoa0708857 PMID: 18650514.
25. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients
in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-
blind, placebo-controlled trial. The Lancet Oncology. 2009; 10(1):25–34. Epub 2008/12/20. https://doi.
org/10.1016/S1470-2045(08)70285-7 PMID: 19095497.
Refractoriness to TACE after resection
PLOS ONE | https://doi.org/10.1371/journal.pone.0214613 April 4, 2019 13 / 14
26. Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness:
a European perspective. Liver cancer. 2014; 3(2):119–24. Epub 2014/06/20. https://doi.org/10.1159/
000343867 PMID: 24945002; PubMed Central PMCID: PMCPMC4057788.
27. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellu-
lar carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society
of Hepatology (JSH) 2010 updated version. Digestive diseases (Basel, Switzerland). 2011; 29(3):339–
64. Epub 2011/08/11. https://doi.org/10.1159/000327577 PMID: 21829027.
28. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH Consensus-Based Clinical Practice
Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study
Group of Japan. Liver cancer. 2014; 3(3–4):458–68. Epub 2015/08/19. https://doi.org/10.1159/
000343875 PMID: 26280007; PubMed Central PMCID: PMCPMC4531423.
29. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, et al. Transarterial chemoembolization
failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014; 87 Suppl 1:22–31. Epub
2014/11/28. https://doi.org/10.1159/000368142 PMID: 25427730.
Refractoriness to TACE after resection
PLOS ONE | https://doi.org/10.1371/journal.pone.0214613 April 4, 2019 14 / 14
